BioHorizon Health Technology Surveillance Update: February 8, 2010

The BioHorizon Health Technology Surveillance Update gives readers a concise,  high level overview of the most important emerging health technology developments on a ongoing basis  including key FDA approvals, substantive clinical trial results and upcoming events of importance. First of all, on behalf of  the entire BioHorizon staff, let me welcome you to the BioHorizon Health [...]

OSI Pharmaceuticals and Genentech’s Tarceva Non-Small Cell Lung Cancer Therapy

On November 18, 2004 OSI Pharmaceuticals and Genentech, Inc. announced that the FDA had approved their cancer therapeutic Tarceva™ (erlotinib). The oral tablet is intended for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. The FDA’s approval of Tarceva was based on results [...]

Avastin

n early December 2003, Genentech announced that the Biologics License Application (BLA) for Avastin (bevacizumab) as a first line therapy in metastatic colorectal cancer had been submitted to the FDA. Genentech requested and received a ‘Priority Review’ designation.